Google parent startup to launch artificial intelligence-designed drug trials by year’s end, teaming up with Eli Lilly and Novartis to tackle major diseases – Alphabet (NASDAQ: GOOGL ), CRISPR Therapeutics (NASDAQ: GOOGL ) :CRSP)

one Google The parent startup is poised to begin clinical trials of its first artificial intelligence-designed drug by the end of the year, marking an upturn in drug development as major tech companies increasingly invest in AI-powered healthcare solutions. Important milestones.

what happened: Isomorphic laboratoryone alphabet inc. Google Subsidiaries focused on major disease areas including oncology, cardiovascular disease, and neurodegenerative diseases Founder Demis Hassabis told the Financial Times in a speech at the World Economic Forum in Davos.

The company has established partnerships with the following companies Eli Lilly and Company Li Lai and Novartis NVS Six drug development projects.

“It usually takes an average of five to ten years to discover a drug. Maybe we can speed that up 10 times, which would be an incredible revolution in human health.

See also: Netflix raises prices 16%, Peter Schiff warns of rising inflation risks ahead of Trump policies

Why it’s important: The announcement comes as Oracle Corporation ORCL Unveiled plans for an artificial intelligence-powered cancer vaccine system capable of delivering personalized treatment within 48 hours. The initiative is part of Stargate, a $500 billion artificial intelligence infrastructure project in partnership with Open artificial intelligence and SoftBank Group.

Investment in AI-driven drug discovery is gaining momentum, Ark Investment CEO Kathy Wood The biologics market opportunity is expected to reach US$400 billion in the next five years. The industry attracts significant attention from investors, although companies like Crispr Therapeutics, Inc. and Intellia Therapeutics Exhibiting considerable market volatility.

Isomorphic Labs, which spun out of Google DeepMind in 2021, represents a growing trend among tech giants to use artificial intelligence to streamline the traditionally long and expensive drug development process.

Read next:

Image from Shutterstock

Disclaimer: This content is generated in part with the help of artificial intelligence tools, and is reviewed and published by Benzinga editors.